UPatch Wearable Ultrasound to Prevent Stillbirths

A Patch That Watches Continuously

UPatch wearable ultrasound represents a departure from episodic prenatal monitoring, one that carries significant implications for how the healthcare industry thinks about foetal surveillance. A research team spanning Stanford University, the University of Oxford, and UC San Diego has published in Nature Biotechnology a proof-of-concept device that can continuously image a foetus and track blood flow in real time, including through moving structures such as the umbilical cord. The device, called UPatch, remains tethered to external electronics and requires a traditional ultrasound for initial placement. The strategic direction is unmistakable. After decades of accepting that meaningful foetal data can only be gathered during brief, scheduled clinic visits, a research consortium with ties to health tech companies has demonstrated a fundamentally different approach.

Why Snapshot Medicine Falls Short

Because the current diagnostic toolkit for pregnancy has a structural limitation clinicians have long learned to work around, continuous monitoring of foetal heart rate and uterine contractions generates a high rate of false alarms. It's a problem. Handheld ultrasound imaging delivers detailed anatomical views but is restricted to a small number of scans across an entire pregnancy, and every one must be performed by a skilled operator. But Prof Sheng Xu of Stanford, a senior author, framed the issue directly.

"Current diagnosis devices are intermittent, that can only capture a snapshot of what's going on with the baby. The patients can only do such measurements in the hospital. They miss a lot of information and data between the hospital visits."

It's a real gap. So clinicians base critical decisions on fragments of data while actual physiological story unfolds unseen between appointments, and it's resisted solution for years not because need was unrecognised but because engineering barriers were substantial.

• Continuous monitoring via existing methods produces false alarms that erode clinician trust and drive unnecessary interventions.
• Handheld imaging is confined to a small number of scans, requires a skilled operator, and captures only a moment in time.

What 52 Pregnancies Revealed

62 pregnant participants in the comparison arm had blood flow from the UPatch measured against conventional handheld devices, and Tom Park, a PhD student at UC San Diego and lead author, reported close agreement. A further 52 pregnant women underwent continuous monitoring, and the data challenged a widely held assumption: foetal blood flow can fluctuate dynamically over time, and temporary changes don't necessarily indicate a persistent problem, Park said. This insight carries weight for a field that has built intervention thresholds around isolated readings. Single time-point measurements, no matter how precise, may mislead as often as they inform. But that framing misses something. The very fluctuations that complicate diagnosis, they're exactly what the device was designed to capture, and distinguishing signal from noise is where the real clinical value will be built.

One Case, One Life Saved

The result wasn't statistical. But in a pre-eclamptic case, the UPatch revealed the severity of intrauterine growth restriction, leading to caesarean delivery to prevent stillbirth, and it caught a condition that might've been missed between scheduled scans because the device watched continuously. Dr Antoniya Georgieva, a senior author from the University of Oxford, stated the implications plainly. "The potential to prevent stillbirth directly is huge," she said. She added that continuous data could open the door to understanding why some babies survive in the womb and others don't, a question that's remained stubbornly difficult to answer with existing tools.

Where the Device Fits Globally

It's not for well-resourced systems. Xu noted they're particularly suited to low-resource areas, including low and middle-income countries, where access to skilled ultrasound operators and frequent hospital visits is far from guaranteed. So the UPatch wearable ultrasound is a potential equaliser in global maternal health, and its eventual utility, assuming successful development beyond proof-of-concept, may be greatest where the current standard of care is thinnest. Diagnostic technologies that reduce dependence on specialist operators and physical infrastructure tend to shift the geography of care, moving data collection from the hospital to the home.

The False Alarm Problem

Obstetric continuous monitoring is checkered. Current methods of tracking foetal heart rate and contractions produce false alarms at a rate that erodes clinician trust and drives unnecessary interventions. A wearable that generates continuous data could, in theory, compound this problem by flooding the clinical workflow with noise. The UPatch wearable ultrasound takes a different route. It images blood flow and structure rather than relying on indirect proxies, and the research team built algorithms to address signal loss caused by foetal movement and the depth of blood vessels. The study's finding that temporary fluctuations don't always signal persistent problems suggests the team is already grappling with the distinction between signal and noise. But that distinction, far more than the hardware itself, may determine whether this technology changes clinical practice.

The Wireless Road Ahead

It's a proof-of-concept device. Tethered to external electronics, it requires initial placement via traditional ultrasound. Park acknowledged the constraints, stating that the team is developing a wireless version and that their long-term vision is a wearable ultrasound system for continuous daily use at home and during normal activities. So that vision, if realised, would transform the device from a research instrument into a consumer-adjacent health product, with all the regulatory and reimbursement questions that such a shift entails. The involvement of researchers with ties to health tech companies hints at commercial intent, though the published work remains in the domain of academic validation.

What Continuous Data Unlocks

Georgieva pointed to an underappreciated dimension. Beyond the clinical use case, continuous monitoring generates a research asset. "For us, having data like this can open the door to learning so much more about what makes some babies survive and others not," she said. This signals a long-term research agenda, not a short-term product launch.

• The device functions as both a potential clinical intervention and a tool for generating new knowledge.
• It promises to build the evidence base that prenatal medicine has lacked because the tools for gathering that evidence did not exist.
• No timeline for commercial availability is offered, and the published work claims no readiness for clinical deployment.

Proof of concept, says Georgieva. This paper marks a very important step because it shows how practically something like continuous, non invasive foetal monitoring can be done outside the hospital, a category that's stubbornly resisted innovation. But the UPatch wearable ultrasound will either be remembered as an early prototype that pointed the way or as the starting point of a new standard of care. So that determination now depends on the engineering work ahead, the regulatory pathway that follows, and the willingness of health systems to reimagine prenatal surveillance as something that happens continuously, not episodically.